Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT06512311

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

Led by Medical University of Vienna · Updated on 2026-04-14

240

Participants Needed

1

Research Sites

390 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Patient derived cell line (PDC) -based drug screening will be applied to formulate a personalized treatment approach.

CONDITIONS

Official Title

Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-75
  • ECOG performance status 0-2
  • Newly diagnosed glioblastoma, IDH wildtype according to the 2021 WHO classification
  • MGMT promotor unmethylated per local investigator
  • Tissue available for drug screening with successful PDC establishment from surgical material
  • Scheduled for concomitant radio-chemotherapy with temozolomide
  • Written informed consent
Not Eligible

You will not qualify if you...

  • Current participation in another therapeutic clinical trial
  • Concurrent malignancy or malignancy within five years prior to study enrollment except carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage I uterine cancer within the last 3 years
  • Pregnant or lactating women
  • Current known infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), except patients with past or resolved HBV infection and patients positive for anti-HCV antibody only if PCR is negative for HCV RNA
  • Known uncontrolled HIV infection; well-controlled HIV requires undetectable viral RNA, CD4+ count 60 cells/mm3, no recent AIDS-defining infections, and stable anti-HIV medications for at least 4 weeks
  • Pre-existing severe peripheral neuropathy (greater than CTCAE grade 2)
  • Hepatic impairment (bilirubin level >1.5x-3x ULN)
  • Kidney dysfunction (CrCl < 59 mL/min)
  • Cardiac dysfunction with left ventricular ejection fraction <60%
  • Any grade of interstitial lung disease
  • History of rhabdomyolysis
  • Acute pancreatitis
  • QTcF 480 msec
  • Diabetes mellitus with fasting glucose > 250mg/dl or 13.9 mmol/L
  • Unable or unwilling to comply with protocol requirements as assessed by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

AKH Vienna, Department for Internal Medicine I, Oncology

Vienna, State of Vienna, Austria, 1090

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here